I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Medicina Interna
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Panminerva Medica 1999 March;41(1):35-8
A pilot study of adjuvant chemotherapy with double modulation of 5-Fluorouracil by Methotrexate and Leucovorin in gastric cancer patients
De Vita F., Orditura M., Auriemma A., Infusino S., Catalano g.
From the Department of Internal and Experimental Medicine “F. Magrassi” Chair of Clinical Oncology II University Medical School of Naples, Naples, Italy
Background. Thirty-four patients with gastric cancer in stage II and III were enrolled, after curative resection, in a pilot study to assess the feasibility and the impact on relapse of a double modulation of 5-Fluorouracil (5FU) by Methotrexate (MTX) and 1-Leucovorin (LFA) as adjuvant chemotherapy.
Methods. The schedule was: MTX 500 mg/m2 d. 1, LFA 250 mg/m2 d.2, 5FU 600 mg/m2 d.2. Cycles were repeated every two weeks for 16 times. Quality of life during treatment was evaluated with the EORTC QLQ-C30.
Results. At a median follow-up of 24 months, 21 (61%) patients treated with postoperative chemotherapy, were disease-free. Toxicity was primarily gastrointestinal, but its intensity was usually mild. The feasibility of treatment was also confirmed from the results of QLQ-C30 questionnaire.
Conclusions. This study demonstrates that the schedule tested is feasible as postoperative treatment in curatively resected gastric cancer patients and prompts the initiation of a randomized trial with a no-treatment control arm.